Treating Cough Due to Non-CF and CF Bronchiectasis With Nonpharmacological Airway Clearance: CHEST Expert Panel Report

Adam T. Hill, Alan F. Barker, Donald C. Bolser, Paul Davenport, Belinda Ireland, Anne B. Chang, Stuart B. Mazzone, Lorcan McGarvey, Todd M. Adams, Kenneth W. Altman, Elie Azoulay, Surinder S. Birring, Fiona Blackhall, Louis Philippe Boulet, Christopher Brightling, Priscilla Callahan-Lyon, Terrie Cowley, Ali A. El Solh, Patricio Escalante, Stephen K. FieldDina Fisher, Cynthia T. French, Peter Gibson, Susan M. Harding, Anthony Harnden, Richard S. Irwin, Peter J. Kahrilas, Joanne Kavanagh, Karina A. Keogh, Kefang Lai, Andrew P. Lane, Kaiser Lim, J. Mark Madison, Mark A. Malesker, Joshua P. Metlay, Alex Molasoitis, Abigail Moore, M. Hassan Murad, Mangala Narasimhan, Huong Q. Nguyen, Peter Newcombe, John Oppenheimer, Marcos I. Restrepo, Mark Rosen, Bruce Rubin, Jay H. Ryu, Sonal Singh, Maeve P. Smith, Susan M. Tarlo, Julie Turmel, Anne E. Vertigan, Gang Wang, Miles Weinberger

Producción científica: Articlerevisión exhaustiva

19 Citas (Scopus)

Resumen

Background: In bronchiectasis due to cystic fibrosis (CF) and other causes, airway clearance is one of the mainstays of management. We conducted a systematic review on airway clearance by using non-pharmacological methods as recommended by international guidelines to develop recommendations or suggestions to update the 2006 CHEST guideline on cough. Methods: The systematic search for evidence examined the question, “Is there evidence of clinically important treatment effects for non-pharmacological therapies in cough treatment for patients with bronchiectasis?” Populations selected were all patients with bronchiectasis due to CF or non-CF bronchiectasis. The interventions explored were the non-pharmacological airway clearance therapies. The comparison populations included those receiving standard therapy and/or placebo. Clinically important outcomes that were explored were exacerbation rates, quality of life, hospitalizations, and mortality. Results: In both CF and non-CF bronchiectasis, there were systematic reviews and overviews of systematic reviews identified. Despite these findings, there were no large randomized controlled trials that explored the impact of airway clearance on exacerbation rates, quality of life, hospitalizations, or mortality. Conclusions: Although the cough panel was not able to make recommendations, they have made consensus-based suggestions and provided direction for future studies to fill the gaps in knowledge.

Idioma originalEnglish (US)
Páginas (desde-hasta)986-993
Número de páginas8
PublicaciónChest
Volumen153
N.º4
DOI
EstadoPublished - abr 1 2018

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine

Huella

Profundice en los temas de investigación de 'Treating Cough Due to Non-CF and CF Bronchiectasis With Nonpharmacological Airway Clearance: CHEST Expert Panel Report'. En conjunto forman una huella única.

Citar esto